Filipa Lynce, MD, is a medical oncologist at MedStar Washington Hospital Center and Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital. In addition, she is an assistant professor of Medicine at Georgetown University.
Dr. Lynce’s clinical practice is focused on breast cancer management, and her research is focused on targeted therapies. She has published her research, on topics including obesity in lymphoma survivors and Avastin (bevacizumab) withdrawal symptoms, in peer-reviewed journals such as Cancer Investigation, Expert Opinion on Pharmacotherapy, and Leukemia and Lymphoma.
Dr. Lynce is a member of the American Society of Clinical Oncology’s (ASCO’s) Workforce Advisory Group, and she previously served on ASCO’s Professional Development Committee and Fellow’s Council. Honors she has achieved include a Lynn Sage Breast Cancer Achievement Award bestowed by Northwestern University. She also received a Young Investigator Award from the Conquer Cancer Foundation/ASCO for her work assessing the cardiac safety of a targeted therapy for patients with human epidermal growth factor receptor 2 (HER2)-positive cancer who also had reduced left ventricular function.
Dr. Lynce is board-certified in oncology, hematology and internal medicine. She is fluent in English, Portuguese and Spanish.
Her medical degree is from the Faculdade de Ciencias Medicas, Universidade Nova Lisboa, Lisbon, Portugal. She completed an internship and residency in internal medicine and a fellowship in hematology/medical oncology at MedStar Washington Hospital Center/MedStar Georgetown University Hospital.
Dr. Lynce’s research interests include
- Breast cancer
- Breast cancer management
- BRCA 1 and 2 mutation carriers
- Triple negative breast cancer
- New treatment options for breast cancer
- Racial disparities.
Safe-Heart: A pilot study assessing the cardiac safety of targeted therapy in patients with HER2-positive breast cancer and reduced left ventricular function
Dr. Lynce serves as principal investigator for this pilot study sponsored by the Conquer Cancer Foundation and Genentech.
Cardiac function in BRCA1 and 2 mutation carriers with a history of breast cancer treated with anthracyclines
Dr. Lynce is a co-investigator on this study of patients with mutations in the BRCA 1 and 2 genes.
Deleterious BRCA 1 and 2 mutations among urban black women
Dr. Lynce was a principal investigator on this study. This retrospective study examined the prevalence of deleterious BRCA 1 and 2 mutations in black women who participated in genetic counseling for hereditary breast and ovarian cancer syndrome.
Pertuzumab for the treatment of breast cancer
Pertuzumab is a new treatment for certain kinds of breast cancer. Dr. Lynce and a colleague studied the development and approval process for this therapy. Their review has been published in Cancer Investigation (2014;32:430-8).
Obesity in adult lymphoma survivors
Survivors of childhood leukemia and lymphoma appear to have an increased prevalence of obesity. In this retrospective study, Dr. Lynce and colleagues studied weight change after lymphoma treatment in an adult population and found that more than 9% of patients had weight gains greater than 20% during follow up. The authors determined that further studies are needed to explore long-term weight trends in these patients. This research has been published in Leukemia and Lymphoma (2012;53:569-574).
- Research Areas